Response to: "A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial".

Madison A, Andersen BL, Ajam A
Arthritis Res Ther 21 65 02/20/2019

Abstract

Full Text